Johnson & Johnson Price to Free Cash Flow Ratio 2010-2022 | JNJ

Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Johnson & Johnson Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-27 168.23 24.75
2022-09-30 162.32 $6.80 23.88
2022-06-30 175.20 $7.60 23.04
2022-03-31 173.83 $1.34 129.84
2021-12-31 166.70 $2.68 62.11
2021-09-30 156.34 $3.92 39.91
2021-06-30 158.53 $2.17 73.00
2020-12-31 149.58 $7.67 19.49
2020-09-30 140.51 $6.91 20.34
2020-06-30 131.85 $6.65 19.83
2020-03-31 122.09 $8.50 14.36
2019-12-31 134.94 $8.64 15.62
2019-09-30 118.86 $9.35 12.72
2019-06-30 127.95 $8.74 14.64
2019-03-31 127.55 $8.04 15.86
2018-12-31 116.98 $7.97 14.69
2018-09-30 124.45 $7.48 16.64
2018-06-30 108.57 $7.70 14.10
2018-03-31 113.82 $7.36 15.46
2017-12-31 123.31 $7.14 17.26
2017-09-30 114.05 $7.11 16.04
2017-06-30 115.31 $6.62 17.41
2017-03-31 107.85 $6.33 17.04
2016-12-31 99.12 $6.03 16.45
2016-09-30 100.93 $9.36 10.79
2016-06-30 102.95 $9.12 11.29
2016-03-31 91.19 $9.58 9.52
2015-12-31 85.95 $11.08 7.75
2021-03-31 157.18 $6.49 24.23
2015-09-30 77.54 $6.13 12.65
2015-06-30 80.33 $6.80 11.81
2015-03-31 82.31 $6.56 12.55
2014-12-31 84.97 $6.85 12.40
2014-09-30 86.05 $6.76 12.74
2014-06-30 83.89 $5.83 14.40
2014-03-31 78.22 $5.49 14.24
2013-12-31 72.41 $4.96 14.59
2013-09-30 68.07 $4.94 13.79
2013-06-30 66.92 $4.71 14.20
2013-03-31 63.06 $4.64 13.59
2012-12-31 53.79 $4.97 10.83
2012-09-30 52.42 $5.02 10.45
2012-06-30 50.93 $5.05 10.08
2012-03-31 49.25 $4.83 10.20
2011-12-31 48.54 $4.59 10.57
2011-09-30 46.70 $4.62 10.10
2011-06-30 48.35 $4.71 10.27
2011-03-31 42.70 $4.72 9.05
2010-12-31 44.17 $5.21 8.48
2010-09-30 43.87 $5.76 7.61
2010-06-30 41.43 $5.69 7.28
2010-03-31 45.32 $5.50 8.24
2009-12-31 44.43 $5.15 8.63
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $441.560B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $330.671B 41.73
Novo Nordisk (NVO) Denmark $311.249B 40.81
Merck (MRK) United States $270.958B 13.95
AbbVie (ABBV) United States $260.674B 10.81
Pfizer (PFE) United States $248.389B 6.79
Novartis AG (NVS) Switzerland $198.780B 14.97